Various retrospective clinical studies have shown that pre- and in-hospital use of low-dose aspirin was associated with a reduced mortality \[[@B1]-[@B4]\], but there is no evidence that NSAIDs may have a similar benefit \[[@B1],[@B5]\]. We studied the medical records of 979 patients with severe sepsis or septic shock who were admitted to a university hospital surgical intensive care unit (ICU). Exclusion criteria were ICU stay of less than 48 hours, age of more than 18 years, and pregnancy. The study was approved by the local ethics committee. Investigators were not required to ask patients for informed consent.

Findings
========

Ninety-three patients had received NSAIDs (that is, ibuprofen, diclofenac, or indomethacin) during their ICU stay. There was no difference in APACHE (Acute Physiology and Chronic Health Evaluation) II score at ICU admission, but there were significant differences in age, gender, and length of ICU stay. In-hospital mortality was about 10% lower in NSAID users in comparison with non-users (Table [1](#T1){ref-type="table"}). Medication during ICU stay with low-dose aspirin, clopidogrel, or statins, all three of which are believed to have a benefit on the outcome in sepsis, is also indicated in Table [1](#T1){ref-type="table"}. A model of stepwise logistic regression with in-hospital mortality as a dependent variable and age, gender, APACHE II score, and the administration of NSAIDs, aspirin, clopidogrel, and statins as independent variables indicated that administration of aspirin during ICU stay was associated with a decreased mortality indicated by an odds ratio (OR) of 0.57 (95% confidence interval 0.39 to 0.83) but that NSAIDs, clopidogrel, statins, and gender were without significant effects. However, when patients on aspirin were excluded from the analysis, NSAIDs were also associated with a reduction of the in-hospital mortality (OR = 0.50, 0.26 to 0.94). On the other hand, the benefit of aspirin (acetylsalicylic acid) was completely abolished in those patients who also received NSAIDs (OR = 1.12, 0.55 to 2.25).

###### 

Characteristics of the patients included in the study

  Variables                        All patients   Without NSAIDs   With NSAIDs   *P*value^a^
  -------------------------------- -------------- ---------------- ------------- -------------
  Number of patients               979            886              93            
  Age, years^b^                    67 (56-75)     67 (57-75)       61 (49-71)    0.001
  Males/Females, percentage        66.2/33.8      64.7/35.3        81.6/19.4     0.002
  APACHE II score^b^               23 (16-29)     23 (16-29)       22 (17-26)    0.160
  Length of stay in ICU, days^b^   13 (6-23)      12 (5-22)        25 (14-18)    0.0001
  Hospital mortality, percentage   42.0           42.9             33.3          0.076
  Co-medication, percentage                                                      
   Aspirin^c^                      28.0           26.7             39.8          0.008
   Clopidogrel                     6.2            6.5              3.2           0.208
   Statins                         21.2           20.4             29.0          0.054

^a^Significant differences between patients without and those with non-steroidal anti-inflammatory drugs (NSAIDs); ^b^values are presented as mean (range); ^c^100 mg/day. APACHE II, Acute Physiology and Chronic Health Evaluation II; ICU, intensive care unit.

The data of the present study indicate that, given separately, both aspirin and NSAIDs may reduce mortality in patients with sepsis. The interaction between aspirin and NSAIDs needs to be considered in forthcoming trials looking for benefits of either compound in patients with sepsis. We speculate that the lack of benefit of parallel use of aspirin and NSAIDs is due to a higher bleeding risk or anti-inflammatory action or both.
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